Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Connecticut Health Center Donaghue Medical Research Foundation |
---|---|
Information provided by: | University of Connecticut |
ClinicalTrials.gov Identifier: | NCT00683280 |
In total, 70 smokers will be randomized to: varenicline alone (an FDA-approved smoking cessation medication) or varenicline plus contingency management (CM) (a behavioral procedure with rewards for target behaviors, like smoking abstinence). Patients in both conditions will receive varenicline for 12 weeks with standard smoking cessation therapy and regular breath and urine sample monitoring for smoking. Patients assigned to CM will earn chances to win prizes for each breath sample that tests negative for smoking, and urine samples that test negative for smoking will result in even greater chances for prizes. More CM patients are expected to achieve and maintain abstinence than patients receiving varenicline alone.
Condition | Intervention | Phase |
---|---|---|
Cigarette Smoking |
Behavioral: contingency management Drug: varenicline (smoking cessation medication) Behavioral: Brief counseling for quitting smoking |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study |
Official Title: | Contingency Management and Pharmacotherapy for Smoking Cessation |
Estimated Enrollment: | 70 |
Study Start Date: | May 2008 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Active Comparator
Medication (varenicline) for 12 weeks (Day 1 through 84) and brief counseling based on public health service guidelines for 5 weeks (Day 1 through 35).
|
Drug: varenicline (smoking cessation medication)
0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.
Behavioral: Brief counseling for quitting smoking
Twice weekly brief counseling based on public health service guidelines for quitting smoking.
|
B: Experimental
Medication (varenicline) for 12 weeks (Day 1 through 84), brief counseling based on public health service guidelines for 5 weeks (Day 1 through 35), plus prize-based contingency management for carbon monoxide samples and urinary cotinine samples that meet smoking abstinence criteria.
|
Behavioral: contingency management
Prize-based contingency management, with the opportunity to earn prizes for expired carbon monoxide levels reading 6ppm or less and urinary cotinine levels reading 30ng/ml or less for 4 weeks.
Drug: varenicline (smoking cessation medication)
0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.
Behavioral: Brief counseling for quitting smoking
Twice weekly brief counseling based on public health service guidelines for quitting smoking.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Ellen M Ciesielski, B.A. | 860-679-4556 | ciesielski@psychiatry.uchc.edu |
United States, Connecticut | |
University of Connecticut Health Center | Recruiting |
Farmington, Connecticut, United States, 06030-3944 | |
Principal Investigator: Sheila M Alessi, Ph.D. |
Principal Investigator: | Sheila M Alessi, Ph.D. | University of Connecticut Health Center |
Responsible Party: | University of Connecticut Health Center ( Sheila Alessi, Ph.D. ) |
Study ID Numbers: | 08-035-3, DF 07-028 |
Study First Received: | May 14, 2008 |
Last Updated: | January 12, 2009 |
ClinicalTrials.gov Identifier: | NCT00683280 |
Health Authority: | United States: Institutional Review Board |
Contingency Management Cigarette Smoking Cessation varenicline |
Smoking Carbon Monoxide |
Habits |